{"id":859458,"date":"2025-06-11T08:07:10","date_gmt":"2025-06-11T12:07:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/"},"modified":"2025-06-11T08:07:10","modified_gmt":"2025-06-11T12:07:10","slug":"vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/","title":{"rendered":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">HIGH POINT, N.C., June  11, 2025  (GLOBE NEWSWIRE) &#8212; vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of\u00a0<em>cadisegliatin<\/em>, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright \u201cHCW@Home\u201d Series, being held virtually on\u00a0Thursday, June 12, 2025.<\/p>\n<p>Conference details are as follows:<\/p>\n<p>\n        <strong>H.C. Wainwright\u00a0\u201cHCW@Home with vTv Therapeutics\u201d<\/strong><br \/>\n        <br \/>Format: Fireside Chat<br \/>Moderator:\u00a0Emily Bodnar, Director, H.C. Wainwright<br \/>vTv Therapeutics Speakers:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Paul Sekhri, Chairman of the Board, President &amp; Chief Executive Officer<\/li>\n<li style=\"margin-bottom:8pt\">Thomas Strack, MD, Chief Medical Officer<\/li>\n<li style=\"margin-bottom:8pt\">Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer<\/li>\n<li style=\"margin-bottom:8pt\">Michael Tung, MD, MBA, Chief Financial Officer<\/li>\n<\/ul>\n<p>Date:\u00a0Thursday, June 12, 2025<br \/>Time:\u00a010:00 AM ET<br \/>Webcast Link: Register<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=go30n7vwcjg7L9194wnfBPnc8y7zzkDmpboNUe6-0lfslu52aDiEdylW3R_VsSmhAkA9eIkPrT1jqhhM7GL7EQnYmoggsoAUGs02d0Gu7VG1bv8TYjjSaF3oYFollDYmWIa1a2mRxY2sI6VQUS_o8w==\" rel=\"nofollow\" target=\"_blank\">\u00a0here<\/a><\/p>\n<p>The webcast of the event will be accessible from News &amp; Events page of the\u00a0vTv\u00a0website.<\/p>\n<p>\n        <strong>About<\/strong>\u00a0<strong>vTv<\/strong>\u00a0<strong>Therapeutics<\/strong><br \/>vTv Therapeutics Inc.\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv&#8217;s clinical pipeline is led by\u00a0<em>cadisegliatin<\/em>, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of\u00a0type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=916YwiHcBQ6CgGbO2KkTz1NTE-_qpXwbPpO6d4NIP83gOqvtYVzJIJ-bHp96a1xgun3TTjwvm-mQRVPWKUEYAyEauVwPl7YL2XWmroP5XuX8xzV-9PT1dZBJDszPXBwp3HFskbly26Tf0NZ1SuwQ8h6vni39CqI8673pYDvDEnO87Y61g_jnRDov9cxWJu9wAjSnQJ8OO4_hclNxBKxvOglJJpZ3aUz_-tvh4gif5BL6IndKBM_2QjvBAZWR45WnygSV76G8InvCVaEnUAHWfQ==\" rel=\"nofollow\" target=\"_blank\">vtvtherapeutics.com<\/a>\u00a0or follow the company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZWeAKwjsP3pF2IXXV9wd0ZLq9qwoZw7GpajjJzyxwid1PFRgmXgdD_Zws4GtuelPUIN7TWp9FQLhEtsijsEFQP75fVrML2FODSDN5653R9vCXzLOLu-Vhnztxe0CyshFQxkld8zHy9PBLoFl2ytxAk3TbtPqChnrgEs5zHl42RhvLqaerqnh889gA7GaTkuaaCsleY_Yk7nBErlnWJolzeJ6GrWGPHhi3DhgtoHYkwhJoFgAoFfCT2RQOpzVis9aXpZsHLLWfOSkqk6v7kj-Ow==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wpF7uexxoaI1hLJ2mPmoU4-EvxOgr8vPXgxDKxUZypiKU7LkmOBjVfAmrfgoIj_MgHxn-AoW_JLiASBQcEems99HDDzBaXbd_MZpXqXfrAB3FwxNFJzfWvo_lr4wA1BGgIEFURO92v6z4hKuvQObS1KNonkuk3AVPABwrRnD3JBx6dBoTm4MwIvr3SfZk3GiSV4gY4J7Ao0OjHqvsLwzYkefVlYW5sVBZv9s960WUq9tbZX5XBJxiVzD3LjxsTcS\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>John Fraunces<br \/>LifeSci Advisors, LLC<br \/>917-355-2395<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IBlf4zXC_MClhXlonhfFM9_VIbD1EGYhzUM8AYrMwd88jXnLsoIZ2vCjpQGO_YonOY_zTYx97RzA6So5EPG3fW4TAj5BadjtclxyjY4-6QpHeEYRSsSVy31gF_LZvMqU\" rel=\"nofollow\" target=\"_blank\">jfraunces@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Caren Begun<br \/>TellMed Strategies<br \/>201-396-8551<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aYu-hniVFGnkdUiRc9CciRl0WPmzF3K5QK3wVbUiiMAyuQtpI39FjG6C6p9f5iKICTsH4muVdrA5JddNAbA58QObsVi-nkjy6U1W6mvx9TyQvbqAG9qApPLl4wL8U3B8ToKN9CJE0oTRGTFdg2uvg5r60OyCTiqXW7k7nn6u4qeafQBxpCYFUVcEQMNsWA3bPoGYvDNSwPLpVO5RFKautpstqnP6kSBAb-0fvX9ND-SJOdMfxYqu6K8A8opN99yqLs663sXscw3dNLrqR8ihLQqAhM-aCJbdSaiqSxIn8Ek=\" rel=\"nofollow\" target=\"_blank\">caren.begun@tmstrat.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjA1Y2NmYzctZjliYS00MDUwLTlmMWYtOTI5MjM1ODVhZjNhLTEwMzEzNjctMjAyNS0wNi0xMS1lbg==\/tiny\/vTv-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) &#8212; vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of\u00a0cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright \u201cHCW@Home\u201d Series, being held virtually on\u00a0Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright\u00a0\u201cHCW@Home with vTv Therapeutics\u201d Format: Fireside ChatModerator:\u00a0Emily Bodnar, Director, H.C. WainwrightvTv Therapeutics Speakers: Paul Sekhri, Chairman of the Board, President &amp; Chief Executive Officer Thomas Strack, MD, Chief Medical Officer Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer Michael Tung, MD, MBA, Chief Financial Officer Date:\u00a0Thursday, June 12, 2025Time:\u00a010:00 AM ETWebcast Link: Register\u00a0here &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859458","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) &#8212; vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of\u00a0cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright \u201cHCW@Home\u201d Series, being held virtually on\u00a0Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright\u00a0\u201cHCW@Home with vTv Therapeutics\u201d Format: Fireside ChatModerator:\u00a0Emily Bodnar, Director, H.C. WainwrightvTv Therapeutics Speakers: Paul Sekhri, Chairman of the Board, President &amp; Chief Executive Officer Thomas Strack, MD, Chief Medical Officer Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer Michael Tung, MD, MBA, Chief Financial Officer Date:\u00a0Thursday, June 12, 2025Time:\u00a010:00 AM ETWebcast Link: Register\u00a0here &hellip; Continue reading &quot;vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-11T12:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series\",\"datePublished\":\"2025-06-11T12:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/\",\"name\":\"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\",\"datePublished\":\"2025-06-11T12:07:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/","og_locale":"en_US","og_type":"article","og_title":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk","og_description":"HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) &#8212; vTv Therapeutics Inc.\u00a0(Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of\u00a0cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright \u201cHCW@Home\u201d Series, being held virtually on\u00a0Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright\u00a0\u201cHCW@Home with vTv Therapeutics\u201d Format: Fireside ChatModerator:\u00a0Emily Bodnar, Director, H.C. WainwrightvTv Therapeutics Speakers: Paul Sekhri, Chairman of the Board, President &amp; Chief Executive Officer Thomas Strack, MD, Chief Medical Officer Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer Michael Tung, MD, MBA, Chief Financial Officer Date:\u00a0Thursday, June 12, 2025Time:\u00a010:00 AM ETWebcast Link: Register\u00a0here &hellip; Continue reading \"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-11T12:07:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series","datePublished":"2025-06-11T12:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/","name":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=","datePublished":"2025-06-11T12:07:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NjcwMCM2OTg1NDg5IzIwMTk3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-the-h-c-wainwright-hcwhome-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"vTv Therapeutics to Participate in the H.C. Wainwright \u201cHCW@Home\u201d Series"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859458"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859458\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}